Nurse Care Management of Opioid Use Disorder Treatment After 3 Years: A Secondary Analysis of the PROUD Cluster Randomized Clinical Trial
11/2024
Journal Article
Authors:
Lapham, G. T.;
Hyun, N.;
Bobb, J. F.;
Wartko, P. D.;
Matthews, A. G.;
Yu, O.;
McCormack, J.;
Lee, A. K.;
Liu, D. S.;
Samet, J. H.;
Zare-Mehrjerdi, M.;
Braciszewski, J. M.;
Murphy, M. T.;
Arnsten, J. H.;
Horigian, V. ;
Caldeiro, R. M.;
Addis, M.;
Bradley, K. A.
Volume:
7
Pagination:
e2447447
Issue:
11
Journal:
JAMA Netw Open
PMID:
39576637
URL:
https://www.ncbi.nlm.nih.gov/pubmed/39576637
DOI:
10.1001/jamanetworkopen.2024.47447
Keywords:
Humans *Opioid-Related Disorders/drug therapy Female Male Adult Middle Aged *Primary Health Care Opiate Substitution Treatment/methods Massachusetts Buprenorphine/therapeutic use Aged Covid-19 Nursing Care Adolescent Young Adult Aged, 80 and over
Abstract:
IMPORTANCE: The Primary Care Opioid Use Disorders (PROUD) treatment trial was a 2-year implementation trial that demonstrated the Massachusetts office-based addiction treatment (OBAT) model of nurse care management for opioid use disorder (OUD) increased OUD treatment in the 2 years after implementation began (8.2 more patient-years of OUD treatment per 10 000 primary care patients). The intervention was continued for a third year, permitting evaluation of 3-year outcomes. OBJECTIVE: To compare OUD medication treatment in intervention and usual care clinics over 3 years of implementation. DESIGN, SETTING, AND PARTICIPANTS: This is a preplanned secondary analysis of a cluster randomized implementation trial, conducted in 6 health systems in 5 states (2 primary care clinics per health system) with clinic randomization stratified by system (assignment notification February 28, 2018 [August 31, 2018, in 1 system]). Data were obtained from electronic health records and insurance claims. Eligible patients were those aged 16 to 90 years visiting intervention or usual care clinics from 3 years before to 2 years after randomization. Patients new to clinics during the third year after randomization could not be included because COVID-19-era transitions to virtual care precluded assignment of patients to clinics. Data analysis occurred from November 2023 to September 2024. INTERVENTION: Clinics were randomized to intervention or care as usual. Intervention included 3 implementation components: salary for 1 full-time OBAT nurse per intervention clinic; training and ongoing technical assistance for nurses; and 3 or more primary care buprenorphine prescribers. MAIN OUTCOME AND MEASURES: Patient-years of OUD treatment (buprenorphine or extended-release naltrexone) per 10 000 primary care patients in the 3 years postrandomization. Mixed-effect models adjusted for baseline values of the outcome and included a health system-specific random intercept to account for correlation of clinic pairs within a system. RESULTS: Prerandomization, a total of 290 071 primary care patients were seen, including 130 618 in intervention clinics (mean [SD] age, 48.6 [17.7] years; mean [SD] female, 59.3% [4.0%]) and 159 453 in usual care clinics (mean [SD] age, 47.2 [17.5] years; mean [SD] female, 64.0% [5.3%]). Over 3 years postrandomization, intervention clinics provided 19.7 (95% CI, 11.1-28.4) more patient-years of OUD treatment per 10 000 primary care patients compared with usual care clinics. CONCLUSIONS: In this secondary analysis of the PROUD cluster randomized trial, after an added year of the intervention, OUD treatment continued to increase in intervention clinics compared with usual care. The treatment increase over 3 years exceeded that of the first 2 years, suggesting that implementation of the Massachusetts OBAT model leads to ongoing increases in OUD treatment among primary care patients in the third year of implementation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03407638.
